Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233730 | 0.94 | KCNH2 (0.36) | KCNH2ACHEALDH1A1TBXA2RPOLB | |
| SCHEMBL4226767 | 0.91 | ALDH1A1 (0.36) | KCNH2ALDH1A1TBXA2RLPAR1LPAR5 | |
| SCHEMBL4235504 | 0.88 | ALDH1A1 (0.41) | KCNH2ACHEALDH1A1TBXA2RPOLB | |
| SCHEMBL4237116 | 0.85 | MEN1 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4226943 | 0.84 | ACHE (0.35) | ACHEPOLBLPAR1LPAR5TTR | |
| SCHEMBL4236446 | 0.79 | MCHR1 (0.35) | ACHE | |
| SCHEMBL4688703 | 0.78 | MEN1 (0.40) | KCNH2ALDH1A1TBXA2RLPAR1LPAR5 | |
| SCHEMBL4228368 | 0.78 | LPAR1 (0.39) | ACHELPAR1LPAR5 | |
| SCHEMBL4231972 | 0.77 | ALDH1A1 (0.40) | KCNH2ALDH1A1TBXA2RLPAR1LPAR5 | |
| SCHEMBL4233453 | 0.73 | ACHE (0.39) | KCNH2ACHEALDH1A1TBXA2RLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | KCNH2 1304/4885ACHE 560/4885ALDH1A1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.